The Research to Accelerate Cures and Equity Act led to an increase in required pediatric studies for recently approved cancer therapies within the first year of the act’s implementation, according to study results.
Researchers presented the findings during American Association for Cancer Research Annual Meeting.
“Significant progress has been made in cancer care and treatment, with many novel therapeutics recently approved. Many of these exciting advancements, however, have not easily translated to new treatment options and approvals for pediatric oncology patients,” Brittany